Ignite Creation Date:
2026-03-26 @ 3:19 PM
Ignite Modification Date:
2026-07-01 @ 1:29 AM
Study NCT ID:
NCT07450833
Status:
COMPLETED
Last Update Posted:
2026-03-05
First Post:
2026-02-18
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers
Sponsor:
Benfovir AG
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Healthy Volunteers | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Benfo-oxythiamine (B-OT) | View |
| None | Oxythiamine | View |
| None | Phase I | View |
| None | Pharmacokinetics | View |
| None | Safety | View |
| None | Transketolase Inhibitor | View |
| None | SARS-CoV-2 | View |
| None | COVID-19 | View |
| None | Prodrug | View |
| None | Thiamine antagonist | View |
| None | Metabolic inhibitor | View |
| None | First-in-human (FIH) | View |
| None | Single Ascending Dose (SAD) | View |
| None | Multiple Ascending Dose (MAD) | View |
| None | Healthy volunteers | View |
| None | Cancer metabolism | View |
| None | Oncology | View |
| None | Metabolic Targets | View |
| None | Solid Tumors | View |
| None | TKTL1 | View |
| None | Transketolase | View |